Kurt McCauley, Director of R&D and Support Services, Mesa Labs and Nicole Robichaud, Scientific and Technical Service Representative, Mesa Labs, give an insight on recent revision of the USP which contains significant changes pertaining to biological indicators
Mesa Labs manufactures its biological indicators (BIs) in accordance with several standards. In a previous edition of Spore News, we discussed the AAMI/ ISO standards which pertain to BIs manufactured for the medical device industry (Spore News Vol 12, no 1). This edition covers BIs manufactured for use in the pharmaceutical industry as detailed in the United States Pharmacopeia (USP). As is the case with any standard that is designed to remain relevant, the USP undergoes periodic revisions. The most recent revision of the USP contains significant changes pertaining to biological indicators and their use in the industry and these will be discussed in this Spore News edition.
A brief history of the USP
The USP was established on January 1, 1820, in the senate chamber of the US capital building. Its purpose was to create a compendium of therapeutic products and provide recipes for their preparation. A comprehensive timeline of changes to the organisation can be found on the USP website1, however, a few dates of interest include:
1 1830 – a Committee of Revision was created and the USP is revised at 10-year intervals.
2 1900 – USP incorporated as a not-for-profit corporation and the Board of Trustees is created.
3 1938 – The Federal Food, Drug, and Cosmetic Act passed and the USP is recognized as official and is enforced by the FDA.
4 1942 – The USP revision cycle is changed from every 10 years to every five years.
5 2002 – The USP is revised and published annually.
Revisions now occur continuously and are presented annually in the USP and twice-annually as Supplements to the USP.
The USP is organised into numerous chapters. General chapters numbered 1 to 999 (i.e. monographs) are considered ‘enforceable’ whereas general chapters numbered greater than 1000 are for informational purposes only.
In the current USP revision, BI content is predominantly in chapters <55> “Biological Indicators—Resistance Performance Tests” and <1229.5> Biological Indicators for Sterilization”, although most chapters in the <1229> series also contain BI references.
BIs and the USP
Biological Indicators are not pharma products so why are they included in the USP? The USP mission statement, “To improve global health through public standards and related programmes that help ensure the quality, safety, and benefit of medicines and foods”, provides the answer. In short, BIs are a tool necessary for assuring the ‘quality’ and ‘safety’ of pharma products and as such, guidance for their preparation and use are included in the USP.
Chapter <55>, considered enforceable, describes the methods and materials used to determine the resistance of BIs and is intended for both the manufacturer and the user. It sets tighter controls for the manufacturers on the use of replicate units per test, while stating “the end users are not required to use the same number of replicates for verification of those determinations.”
A comparison of differences between the current revision and the previous version of chapter <55> is presented in Appendix 1. The most significant change is that all BI information has been deleted from the official monographs section and much of it relocated in chapter <55>. This table is not all inclusive and the reader should refer to the USP for complete details.
New informational chapters to the USP are numbered in the <1229> series and largely replace the deleted chapter <1035> “Biological Indicators for Sterilization”. This series provides a well written and easy to understand description of the basic principles for control of a sterilization process including, process development, process validation, and maintenance/ monitoring.
As Biological Indicators are tools that are used in each of these steps, they are discussed throughout most of the <1229> series which include:
- <1229> Sterilisation of Compendial Articles
- <1229.1> Steam Sterilisation by Direct Contact
- <1229.2> Moist Heat Sterilisation of Aqueous Liquids
- <1229.3> Monitoring of Bioburden
- <1229.4> Sterilisation Filtration of Liquids
- <1229.5> Biological Indicators for Sterilisation
- <1229.6> Liquid Phase Sterilisation
- <1229.7> Gaseous Sterilisation
- <1229.8> Dry Heat
- <1229.9> Physicochemical Integrators and Indicators for Sterilisation
- <1229.10> Radiation Sterilisation
- <1229.11> Vapor Phase Sterilisation
- <1229.12> New Sterilisation methods
A comparison between the <1229> chapters and the deleted chapter <1035> is presented in Appendix 2. This table is not all inclusive and the reader should refer to the USP for complete details.
It is our opinion that the latest revision of the USP provides significant improvements in both its organisation and presentation of the biological indicator subject matter. Some of the values previously presented in the general information chapter (e.g. the D-value ranges in chapter <1035>) were interpreted by many firms to be enforceable, and as such caused some confusion. These have been removed in the latest revision. Additionally, the USP increasingly references existing standards that meet their expectations (e.g. ISO 11138 series-Biological Indicators, and ISO 18472-Resistometers), rather than create a redundant set of standards.